Stock Scorecard
Stock Summary for Ligand Pharmaceuticals Inc - Class B (LGND) - $200.33 as of 12/19/2025 8:01:53 PM EST
Total Score
9 out of 30
Safety Score
59 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for LGND
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for LGND
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for LGND
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for LGND
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for LGND (59 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 8 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 6 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 2 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for LGND
Financial Details for LGND
Company Overview |
|
|---|---|
| Ticker | LGND |
| Company Name | Ligand Pharmaceuticals Inc - Class B |
| Country | USA |
| Description | Ligand Pharmaceuticals Incorporated (LGND) is a leading biopharmaceutical company based in San Diego, California, focused on enhancing drug discovery and development through its advanced technologies and strategic global partnerships. The firm offers a robust portfolio of proprietary solutions aimed at improving drug efficacy and accelerating market entry across various therapeutic areas, including oncology and rare diseases. With a strong management team and an emphasis on collaboration, Ligand is strategically positioned to capitalize on emerging opportunities in the evolving pharmaceutical industry, driving both sustainable growth and operational efficiencies. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/4/2026 |
Stock Price History |
|
| Last Day Price | 200.33 |
| Price 4 Years Ago | 154.46 |
| Last Day Price Updated | 12/19/2025 8:01:53 PM EST |
| Last Day Volume | 427,546 |
| Average Daily Volume | 238,524 |
| 52-Week High | 212.49 |
| 52-Week Low | 93.58 |
| Last Price to 52 Week Low | 114.07% |
Valuation Measures |
|
| Trailing PE | 84.86 |
| Industry PE | 53.65 |
| Sector PE | 126.11 |
| 5-Year Average PE | 21.63 |
| Free Cash Flow Ratio | 28.30 |
| Industry Free Cash Flow Ratio | 11.46 |
| Sector Free Cash Flow Ratio | 26.50 |
| Current Ratio Most Recent Quarter | 24.69 |
| Total Cash Per Share | 7.08 |
| Book Value Per Share Most Recent Quarter | 48.34 |
| Price to Book Ratio | 4.00 |
| Industry Price to Book Ratio | 59.73 |
| Sector Price to Book Ratio | 26.03 |
| Price to Sales Ratio Twelve Trailing Months | 15.09 |
| Industry Price to Sales Ratio Twelve Trailing Months | 33.32 |
| Sector Price to Sales Ratio Twelve Trailing Months | 19.08 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 19,681,700 |
| Market Capitalization | 3,942,834,961 |
| Institutional Ownership | 106.68% |
Dividends |
|
| Ex-Dividend Date | 7/2/2010 |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.4560 |
| Total Years Dividend Increasing | 0 |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | -96.96% |
| 3-Year Dividend Growth Rate Percentage | -96.96% |
| 5-Year Dividend Growth Rate Percentage | -96.96% |
| All-Time Dividend Growth Rate Percentage | -96.96% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 103.20% |
| Annual Earnings Growth | -107.73% |
| Reported EPS 12 Trailing Months | 2.27 |
| Reported EPS Past Year | 4.66 |
| Reported EPS Prior Year | 5.71 |
| Net Income Twelve Trailing Months | 48,581,000 |
| Net Income Past Year | -4,032,000 |
| Net Income Prior Year | 52,154,000 |
| Quarterly Revenue Growth YOY | 122.80% |
| 5-Year Revenue Growth | 6.80% |
| Operating Margin Twelve Trailing Months | 46.90% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 139,376,000 |
| Total Cash Past Year | 72,307,000 |
| Total Cash Prior Year | 22,954,000 |
| Net Cash Position Most Recent Quarter | -306,117,000 |
| Net Cash Position Past Year | -4,388,000 |
| Long Term Debt Past Year | 76,695,000 |
| Long Term Debt Prior Year | 76,695,000 |
| Total Debt Most Recent Quarter | 445,493,000 |
| Equity to Debt Ratio Past Year | 0.92 |
| Equity to Debt Ratio Most Recent Quarter | 0.68 |
| Total Stockholder Equity Past Year | 830,439,000 |
| Total Stockholder Equity Prior Year | 700,913,000 |
| Total Stockholder Equity Most Recent Quarter | 950,171,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 30,758,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 1.56 |
| Free Cash Flow Past Year | 77,407,000 |
| Free Cash Flow Prior Year | -4,272,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -1.26 |
| MACD Signal | -0.84 |
| 20-Day Bollinger Lower Band | 145.78 |
| 20-Day Bollinger Middle Band | 179.40 |
| 20-Day Bollinger Upper Band | 213.01 |
| Beta | 0.86 |
| RSI | 52.29 |
| 50-Day SMA | 137.71 |
| 150-Day SMA | 99.47 |
| 200-Day SMA | 96.60 |
System |
|
| Modified | 12/18/2025 2:46:26 AM EST |